Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

J. Cortes, MD, T. Bruemmendorf, MD, H. Kantarjian, MD, J. Khoury, MD, G. Rosti, MD, T. Fischer, MD, L. Tornaghi, MD, B. Hewes, MD, E.C. Martin, MD, C. Gambacorti-Passerini, MD

Blood (2007) 110 (11): 733.

https://doi.org/10.1182/blood.V110.11.733.733

Published: 2007

Journal Articles

Imatinib and Pregnancy.

S. Pye, Jorge Cortes, G. Rosti, P. Ault, T. Oliveto, R. Pilot, Hagop M. Kantarjian, Alan Hatfield, J. Apperley

Blood (2006) 108 (11): 431.

https://doi.org/10.1182/blood.V108.11.431.431

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results from the CA180-015 ‘START-L’ Study.

Herve Dombret, O.G. Ottmann, G. Rosti, B. Simonsson, R.A. Larson, A. Gollerkeri, A. Apanovitch, J. Radich, Steven Coutre

Blood (2006) 108 (11): 286.

https://doi.org/10.1182/blood.V108.11.286.286

Published: 2006

Journal Articles

A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

Blood (2006) 108 (11): 4779.

https://doi.org/10.1182/blood.V108.11.4779.4779

Published: 2006

Journal Articles

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Ilaria Iacobucci, Giovanni Martinelli, M. Amabile, A. Poerio, S. Soverini, F. Castagnetti, S. Colarossi, A. Gnani, N. Testoni, M. Breccia, E. Abruzzese, B. Martino, D. Cilloni, G. Saglio, F. Pane, G. Rosti, M. Baccarani

Blood (2006) 108 (11): 2156.

https://doi.org/10.1182/blood.V108.11.2156.2156

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

Jorge Cortes, D.W. Kim, F. Guilhot, G. Rosti, R.T. Silver, A. Gollerkeri, P. Agarwal, S. Branford, J.F. Apperley

Blood (2006) 108 (11): 2160.

https://doi.org/10.1182/blood.V108.11.2160.2160

Published: 2006

Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

M. Talpaz, P. Rousselot, D.W. Kim, F. Guilhot, S. Corm, E. Bleickardt, R. Zink, G. Rosti, S. Coutre, C. Sawyers

Blood (2005) 106 (11): 40.

https://doi.org/10.1182/blood.V106.11.40.40

Published: 2005

NARROW

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

Imatinib and Pregnancy.

Dasatinib (SPRYCEL®) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results from the CA180-015 ‘START-L’ Study.

A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

Imatinib and Pregnancy.

Dasatinib (SPRYCEL®) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results from the CA180-015 ‘START-L’ Study.

A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only